Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
IPO watch 2024: Which new stocks will hit the market?
Cramer names biopharma companies to watch as industry mergers start to pile up
RAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZB
Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target
Yes Virginia, There Is a Santa Claus Rally
Bristol Myers Squibb Buys RayzeBio, Its Second Multibillion-Dollar Deal in Days
Midday Movers: Intel's Israel Deal, Bristol-Myers Squibb Buys RayzeBio
Bristol Myers Squibb goes back to the acquisition well with $4.1B purchase of RayzeBio
Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%
Shareholder Alert: Ademi LLP investigates whether RayzeBio, Inc. has obtained a Fair Price in its transaction with Bristol Myers
Why Is RayzeBio (RYZB) Stock Up 100% Today?
RYZB Stock Alert: Halper Sadeh LLC Is Investigating RayzeBio, Inc.
Bristol Myers to buy RayzeBio for about $4.1B
Nano Dimension Buys Stratasys, Bristol Myers's Shopping Spree, Apple Gets a ‘No'
RayzeBio: New IPO With Good Data And Solid Premise
Bristol Myers strikes $4.1 bln RayzeBio deal for targeted cancer therapies
Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
Bristol Myers to buy RayzeBio for more than 100% premium, in a deal valued at $4.1 billion
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
The 2023 IPO scene: Biggest hits and misses
RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
RayzeBio to Participate in Upcoming Investor Conferences in November 2023
RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors
RayzeBio: Initiating Coverage With Buy Rating And A Price Target Of $43
RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
IPO market recovering with strong ARM and RayzeBio debuts; Instacart, Birkenstock and more to come
RayzeBio stock opens with a big gain, to push valuation up to $1.4 billion
RayzeBio to go public at $1B market valuation
RayzeBio valued at nearly $1 billion as upsized IPO prices at top of expected range
RayzeBio, Inc. Announces Pricing of Upsized $311 Million Initial Public Offering
IPO Update: RayzeBio Readies $245 Million IPO
RayzeBio sets IPO terms, to be valued at up to $1 billion
RayzeBio Appoints Christy Oliger to its Board of Directors
Late Stage Biopharma RayzeBio Files For U.S. IPO